CHMP recommends Novartis's antihypertensive Exforge HCT
This article was originally published in Scrip
Executive Summary
The CHMP has recommended Novartis's Exforge HCT (amlodipine besylate plus valsartan plus hydrochlorothiazide) for marketing authorisation in the EU for the treatment of hypertension in adults.